Synthetic Biologics Inc (SYN) Given Average Rating of “Hold” by Analysts
Shares of Synthetic Biologics Inc (NYSEMKT:SYN) have earned a consensus recommendation of “Hold” from the six research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $5.50.
A number of brokerages have recently commented on SYN. ValuEngine raised Synthetic Biologics from a “strong sell” rating to a “sell” rating in a report on Friday, August 18th. Zacks Investment Research raised Synthetic Biologics from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a report on Wednesday, August 9th.
Synthetic Biologics (NYSEMKT SYN) opened at 0.8751 on Wednesday. Synthetic Biologics has a 52 week low of $0.41 and a 52 week high of $1.63. The firm has a 50-day moving average of $0.86 and a 200 day moving average of $0.64. The firm’s market capitalization is $112.23 million.
Synthetic Biologics (NYSEMKT:SYN) last issued its quarterly earnings results on Thursday, August 3rd. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.03. Analysts predict that Synthetic Biologics will post ($0.17) earnings per share for the current year.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. boosted its position in Synthetic Biologics by 8,102.7% during the 2nd quarter. Goldman Sachs Group Inc. now owns 1,129,108 shares of the company’s stock worth $639,000 after acquiring an additional 1,115,343 shares during the period. LMR Partners LLP acquired a new stake in Synthetic Biologics during the 2nd quarter worth about $194,000. Bank of New York Mellon Corp boosted its position in Synthetic Biologics by 3.1% during the 1st quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock worth $166,000 after acquiring an additional 7,962 shares during the period. UBS Group AG boosted its position in Synthetic Biologics by 10.3% during the 1st quarter. UBS Group AG now owns 214,357 shares of the company’s stock worth $135,000 after acquiring an additional 20,038 shares during the period. Finally, Susquehanna International Group LLP boosted its position in Synthetic Biologics by 76.4% during the 2nd quarter. Susquehanna International Group LLP now owns 189,342 shares of the company’s stock worth $107,000 after acquiring an additional 82,030 shares during the period.
About Synthetic Biologics
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.